Hutchinson-Gilford Progeria Syndrome (HGPS) Market Report 2026

Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview

• Hutchinson-Gilford Progeria Syndrome (HGPS) market size has reached to $106.25 billion in 2025 • Expected to grow to $160 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: The Increase In Funding For Research And Development Drives Market Growth • Market Trend: Advancement Of Progerin-Targeted Therapeutics Driving Next-Generation Treatment Approaches In HGPS • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hutchinson-Gilford Progeria Syndrome (HGPS) Market?

Hutchinson-Gilford Progeria Syndrome (HGPS), commonly known as progeria, is an extremely rare and fatal genetic disorder that causes accelerated aging in children. It is caused by mutations in the LMNA gene, leading to symptoms such as growth delays, hair loss, premature wrinkling of the skin, and cardiovascular issues. The average life expectancy for individuals with progeria is approximately 14.5 years. The main types of hutchinson-gilford progeria syndrome (HGPS) treatment are farnesyltransferase inhibitors (zokinvy (lonafarnib)), low-dose aspirin, physical and occupational therapy, hearing aids, genetic counseling, and others. Farnesyltransferase inhibitors, like Zokinvy (lonafarnib), block the enzyme responsible for protein modification, offering a targeted treatment for HGPS that may improve outcomes by preventing premature aging in children. It is administered through various routes of administration, such as oral, injectable, intravenous, and transdermal, with several mechanisms of action, including antisense oligonucleotides, CRISPR-Cas9 gene editing, ribonucleic acid (RNA) interference, and targeted drug delivery systems. It is used by various end-users, such as hospitals, specialty clinics, academic and research institutes, and others.

What Is The Hutchinson-Gilford Progeria Syndrome (HGPS) Market Growth Forecast?

The hutchinson-gilford progeria syndrome (hgps) market size is expected to see strong growth in the next few years. It will grow to $160 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to advancements in gene therapy and crispr-cas9 technologies, growing investment in ultra-rare disease research, expanding clinical trials for disease-modifying therapies, increasing global awareness of progeria, rising regulatory support for orphan drugs. Major trends in the forecast period include increasing focus on gene editing and antisense therapies for progeria, growing adoption of targeted drug therapies such as farnesyltransferase inhibitors, rising emphasis on early genetic diagnosis and counseling, expansion of multidisciplinary supportive care models, increasing research collaboration for ultra-rare pediatric disorders.

Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market Segmentation

1) By Treatment Type: Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)), Low-dose Aspirin, Physical And Occupational Therapy, Hearing Aids, Genetic Counseling, Other Treatment Types 2) By Mechanism Of Action: Antisense Oligonucleotides, Crispr-cas9 Gene Editing, Rna Interference, Targeted Drug Delivery Systems 3) By End-User: Hospitals, Specialty Clinics, Academic And Research Institutes, Other End-Users Subsegments: 1) By Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)): Monotherapy With Lonafarnib, Combination Therapy With Other Drugs 2) By Low-dose Aspirin: Cardiovascular Protection, Anti-inflammatory Therapy 3) By Physical And Occupational Therapy: Mobility Support And Rehabilitation, Joint And Bone Health Management, Adaptive Equipment For Daily Activities 4) By Hearing Aids: Conventional Hearing Aids, Bone-Anchored Hearing Aids (BAHA), Cochlear Implants 5) By Genetic Counseling: Family Genetic Testing, Genetic Risk Assessment, Prenatal Counseling And Guidance 6) By Other Treatment Types: Stem Cell Therapy, Gene Editing and Therapy, Nutritional Support And Management

What Is The Driver Of The Hutchinson-Gilford Progeria Syndrome (HGPS) Market?

The increase in funding for research and development of new therapies is expected to propel the growth of the hutchinson-gilford progeria syndrome (HGPS) market going forward. Funding for Research and Development refers to financial resources allocated to innovate, improve, and advance scientific knowledge and technological solutions. An increase in funding for research and development is attributed to factors such as rising demand for innovative treatments and government support for healthcare advancements. Increased funding for research and development accelerates the advancement of treatments for hutchinson-gilford Progeria Syndrome by supporting clinical trials and fostering innovative therapies. It drives progress in understanding the genetic origins of the condition and facilitates the development of targeted solutions. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, the increase in funding for research and development of new therapies is driving the growth of the hutchinson-gilford progeria syndrome (HGPS) industry.

Key Players In The Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market

Major companies operating in the hutchinson-gilford progeria syndrome (hgps) market are Sentynl Therapeutics, Progeria Research Foundation, National Institutes of Health, Boston Children's Hospital, Children's Hospital of Philadelphia, Johns Hopkins Hospital, Mayo Clinic, Cleveland Clinic, Mount Sinai, Duke University, St Jude Children's Research Hospital, Cincinnati Children's Hospital Medical Center, Children’s Hospital Los Angeles, Harvard Medical School, The Scripps Research Institute, Blueprint Genetics, AnGes MG Inc., PRG Science & Technology Co. Ltd., University of Maryland School of Medicine, UCLA Health

Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market Trends and Insights

Major companies operating in the Hutchinson Gilford Progeria Syndrome (HGPS) market are focusing on antisense and small-molecule progerin modulating agents, such as Progerinin, to gain a competitive advantage. For instance, in October 2024, PRG Science & Technology, a South Korea–based biotech company, received FDA clearance to begin a Phase 2a clinical trial of Progerinin. This oral therapy is designed to reduce the buildup of progerin and will be evaluated alongside Zokinvy. The combined approach aims to address the underlying biological cause of Hutchinson-Gilford Progeria Syndrome (HGPS), rather than focusing solely on downstream symptoms. While the strategy shows potential to advance treatment beyond current options, its long-term effectiveness and safety in children still need to be confirmed through further research and clinical evaluation.

What Are Latest Mergers And Acquisitions In The Hutchinson-Gilford Progeria Syndrome (HGPS) Market?

In May 2024, Sentynl Therapeutics, Inc., a US-based biopharmaceutical company, acquired Zokinvy from Eiger BioPharmaceuticals, Inc. for an undisclosed amount. By acquiring Zokinvy, Sentynl seeks to address the unmet medical needs of patients suffering from ultra-rare genetic conditions, which lead to accelerated aging and significantly reduced life expectancy. Eiger BioPharmaceuticals, Inc. is a US-based biopharmaceutical that developed Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS).

Regional Outlook

North America was the largest region in the hutchinson-gilford progeria syndrome (HGPS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hutchinson-Gilford Progeria Syndrome (HGPS) Market?

The hutchinson-gilford progeria syndrome (HGPS) market consists of revenues earned by entities by providing services such as genetic testing and diagnosis, drug development and clinical trials, specialized medical care and treatment, and patient support and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hutchinson-gilford progeria syndrome (HGPS) market also includes sales of pharmaceutical drugs, genetic testing kits, medical devices and monitoring equipment, nutritional supplements and special diet products, and assistive mobility devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hutchinson-Gilford Progeria Syndrome (HGPS) Market Report 2026?

The hutchinson-gilford progeria syndrome (hgps) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hutchinson-gilford progeria syndrome (hgps) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.